Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huayong No.1 compound probiotics
- Development stage
- Preclinical
- Lead developer
- The Affiliated Brain Hospital of Guangzhou Medical University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Huayong No.1 compound probiotics is a multi-strain probiotic formulation developed for the adjunctive treatment of psychiatric disorders, specifically major depressive disorder (MDD) with comorbid anxiety symptoms. Developed by The Affiliated Brain Hospital of Guangzhou Medical University, the therapy is designed to modulate the gut-microbiota-brain axis to alleviate depressive and anxiety symptoms, improve cognitive function, and mitigate gastrointestinal distress. The formulation is typically administered orally as a supplement to standard antidepressant therapy. It is currently being evaluated in randomized, double-blind, placebo-controlled clinical trials to assess its efficacy in improving clinical outcomes and modulating biological markers associated with the gut-brain axis in adult patients.
- Brand names
- Huayong No.1
- Other names
- Huayong No.1 compound probioticsHuayong No. 1Huayong No.1 Probiotics
Beyond the preview
Go deeper on Huayong No.1 compound probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huayong No.1 compound probiotics.